This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignees: National Institute of Health and Medical Research, Assistance Publique-Hopitaux De Paris, Centre National De La Recherche Scientifique. Active years: 2014.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 1,853 
1 out of 331 
1 out of 5,383 
Years Active: 2014
Title: Hakim Ahmed-Belkacem: Innovator in Cyclophilin Inhibitors
Introduction
Hakim Ahmed-Belkacem is a notable inventor based in Créteil, France. He has made significant contributions to the field of medicinal chemistry, particularly in the development of inhibitors for cyclophilins. With a total of 2 patents, his work has implications for various therapeutic applications.
Latest Patents
Among his latest patents is a groundbreaking invention titled "Inhibitors of Cyclophilins and Uses Thereof." This invention relates to a compound of formula (I), which has potential applications in treating diseases associated with cyclophilin activity. The innovative nature of this compound highlights Ahmed-Belkacem's commitment to advancing medical science.
Career Highlights
Throughout his career, Hakim Ahmed-Belkacem has worked with prestigious institutions such as the Institut National de la Santé et de la Recherche Médicale and Université de Montpellier. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to significant research initiatives.
Collaborations
Some of his notable coworkers include Jean-François Alexandre Guichou and Lionel Colliandre. Their collaborative efforts have further enriched the research landscape in which Ahmed-Belkacem operates.
Conclusion
Hakim Ahmed-Belkacem's contributions to the field of cyclophilin inhibitors demonstrate his innovative spirit and dedication to advancing medical research. His patents and collaborations reflect a commitment to improving therapeutic options for various health conditions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile